Land: Schweden
Sprache: Schwedisch
Quelle: Läkemedelsverket (Medical Products Agency)
acetylsalicylsyra
Krka d.d., Novo mesto
B01AC06
acetylsalicylic acid
160 mg
Enterotablett
acetylsalicylsyra 160 mg Aktiv substans; natriumlaurilsulfat Hjälpämne; laktosmonohydrat Hjälpämne
Receptbelagt
Avregistrerad
2017-01-13
ERROR! UNKNOWN DOCUMENT PROPERTY NAME. ERROR! UNKNOWN DOCUMENT PROPERTY NAME. ERROR! UNKNOWN DOCUMENT PROPERTY NAME. ERROR! UNKNOWN DOCUMENT PROPERTY NAME. ERROR! UNKNOWN DOCUMENT PROPERTY NAME. ERROR! UNKNOWN DOCUMENT PROPERTY NAME. ERROR! UNKNOWN DOCUMENT PROPERTY NAME. ERROR! UNKNOWN DOCUMENT PROPERTY NAME. ERROR! UNKNOWN DOCUMENT PROPERTY NAME. ERROR! UNKNOWN DOCUMENT PROPERTY NAME. – Updated: ERROR! UNKNOWN DOCUMENT PROPERTY NAME. Page 1 of 9 PACKAGE LEAFLET: INFORMATION FOR THE USER BARTAL 75 MG GASTRO-RESISTANT TABLETS BARTAL 100 MG GASTRO-RESISTANT TABLETS BARTAL 160 MG GASTRO-RESISTANT TABLETS acetylsalicylic acid _[For medicines available only on prescription:]_ READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. _[For medicines available without a prescription:]_ READ ALL OF THIS LEAFLET CAREFULLY BEFORE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist or nurse has have told you. - Keep this leaflet. You may need to read it again. - Ask your pharmacist if you need more information or advice. - If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. - You must talk to a doctor if you do not feel better or if you feel worse. WHAT IS IN THIS LEAFLET 1. What Lesen Sie das vollständige Dokumentis and what it is used for 2. What you need to know before you take 3. How to take 4. Possible s
ERROR! UNKNOWN DOCUMENT PROPERTY NAME. ERROR! UNKNOWN DOCUMENT PROPERTY NAME. ERROR! UNKNOWN DOCUMENT PROPERTY NAME. ERROR! UNKNOWN DOCUMENT PROPERTY NAME. ERROR! UNKNOWN DOCUMENT PROPERTY NAME. ERROR! UNKNOWN DOCUMENT PROPERTY NAME. ERROR! UNKNOWN DOCUMENT PROPERTY NAME. ERROR! UNKNOWN DOCUMENT PROPERTY NAME. ERROR! UNKNOWN DOCUMENT PROPERTY NAME. ERROR! UNKNOWN DOCUMENT PROPERTY NAME. – Updated: ERROR! UNKNOWN DOCUMENT PROPERTY NAME. Page 1 of 15 1. NAME OF THE MEDICINAL PRODUCT Bartal 75 mg gastro-resistant tablets Bartal 100 mg gastro-resistant tablets Bartal 160 mg gastro-resistant tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each gastro-resistant tablet contains 75 mg, 100 mg or 160 mg acetylsalicylic acid. Excipients with known effect: 75 mg: Lactose monohydrate .......................................................................................45 mg per tablet. Sunset yellow (E110) ................................................................................0.0006 mg per tablet. 100 mg: Lactose monohydrate…………………………………………………………60 mg per tablet 160 mg: Lactose monohydrate .......................................................................................96 mg per tablet. Lecithin (soya) (E322) ..................................................................................0.42 mg per tablet. For the full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Gastro-resistant tablet75 mg: pink, round biconvex film-coated tablets with a diameter of about 7.2 mm. Lesen Sie das vollständige Dokument100 mg: white, round, biconvex film-coated tablets with a diameter of about 8.1 mm. 160 mg: yellow, round, biconvex film-coated tablets with a diameter of about 9.2 mm. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS - Secondary prevention of myocardial infarction. - Prevention of cardiovascular morbidity in patients suffering from stable angina pectoris. - History of unstable angina pectoris, except during the acute phase. - Prev